Abstract
Prostate cancer is the leading internal malignancy in men with an age over 50. Therapeutic options for patients with recurrence after hormonal therapy are limited. New therapeutic options are needed. In our previous studies, we demonstrated the efficacy and safety of 'suicide gene therapy' using herpes simplex virus-thymidine kinase gene transduction and ganciclovir therapy in an orthotopic mouse model. These preclinical studies resulted in the initiation of clinical trials using this approach in USA and Japan. Safety and positive clinical response were shown in these clinical studies. In this review article, current status of prostate cancer 'suicide' gene therapy is updated and future direction of its development is also discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 1257-1265 |
| Number of pages | 9 |
| Journal | Nihon rinsho. Japanese journal of clinical medicine |
| Volume | 61 |
| Issue number | 7 |
| Publication status | Published - 2003 |
Fingerprint
Cite this
Suicide gene therapy for prostate cancer--update of current development. / Ebara, Shin; Nasu, Yasutomo.
In: Nihon rinsho. Japanese journal of clinical medicine, Vol. 61, No. 7, 2003, p. 1257-1265.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Suicide gene therapy for prostate cancer--update of current development
AU - Ebara, Shin
AU - Nasu, Yasutomo
PY - 2003
Y1 - 2003
N2 - Prostate cancer is the leading internal malignancy in men with an age over 50. Therapeutic options for patients with recurrence after hormonal therapy are limited. New therapeutic options are needed. In our previous studies, we demonstrated the efficacy and safety of 'suicide gene therapy' using herpes simplex virus-thymidine kinase gene transduction and ganciclovir therapy in an orthotopic mouse model. These preclinical studies resulted in the initiation of clinical trials using this approach in USA and Japan. Safety and positive clinical response were shown in these clinical studies. In this review article, current status of prostate cancer 'suicide' gene therapy is updated and future direction of its development is also discussed.
AB - Prostate cancer is the leading internal malignancy in men with an age over 50. Therapeutic options for patients with recurrence after hormonal therapy are limited. New therapeutic options are needed. In our previous studies, we demonstrated the efficacy and safety of 'suicide gene therapy' using herpes simplex virus-thymidine kinase gene transduction and ganciclovir therapy in an orthotopic mouse model. These preclinical studies resulted in the initiation of clinical trials using this approach in USA and Japan. Safety and positive clinical response were shown in these clinical studies. In this review article, current status of prostate cancer 'suicide' gene therapy is updated and future direction of its development is also discussed.
UR - http://www.scopus.com/inward/record.url?scp=0141613714&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141613714&partnerID=8YFLogxK
M3 - Article
VL - 61
SP - 1257
EP - 1265
JO - Nippon rinsho. Japanese journal of clinical medicine
JF - Nippon rinsho. Japanese journal of clinical medicine
SN - 0047-1852
IS - 7
ER -